Attached files
| file | filename |
|---|---|
| EX-4.2 - EXHIBIT 4.2 - ENZON PHARMACEUTICALS, INC. | v434165_ex4-2.htm |
| EX-31.2 - EXHIBIT 31.2 - ENZON PHARMACEUTICALS, INC. | v434165_ex31-2.htm |
| EX-21.1 - EXHIBIT 21.1 - ENZON PHARMACEUTICALS, INC. | v434165_ex21-1.htm |
| EX-32.2 - EXHIBIT 32.2 - ENZON PHARMACEUTICALS, INC. | v434165_ex32-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ENZON PHARMACEUTICALS, INC. | v434165_ex31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - ENZON PHARMACEUTICALS, INC. | v434165_ex23-1.htm |
| EX-10.29 - EXHIBIT 10.29 - ENZON PHARMACEUTICALS, INC. | v434165_ex10-29.htm |
| EX-10.28 - EXHIBIT 10.28 - ENZON PHARMACEUTICALS, INC. | v434165_ex10-28.htm |
| 10-K - FORM 10-K - ENZON PHARMACEUTICALS, INC. | v434165_10k.htm |
| EX-10.27 - EXHIBIT 10.27 - ENZON PHARMACEUTICALS, INC. | v434165_ex10-27.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Enzon Pharmaceuticals, Inc. (the Company) on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, George W. Hebard III, Interim Principal Executive Officer, Interim Chief Operating Officer and Secretary of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| March 21, 2016 | /s/ George W. Hebard III |
| George W. Hebard III | |
| Interim Principal Executive Officer, Interim | |
| Chief Operating Officer and Secretary | |
| (Principal Executive Officer) |
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Enzon Pharmaceuticals, Inc. and will be furnished to the Securities Exchange Commission or its staff upon request.